Sign in with Google
IND Forms
Join our community on Telegram!
Join the biggest community of Pharma students and professionals.
IND FORMS – STRUCTURED REGULATORY FRAMEWORK
Investigational New Drug submissions to the US Food and Drug Administration require mandatory regulatory forms that establish sponsor accountability, investigator qualification, financial transparency, and compliance with federal regulations under 21 CFR Part 312. These forms are legally binding and form the administrative backbone of the IND submission. A Regulatory Affairs professional must understand not only what each form is, but when it is required, who signs it, and how it integrates into the lifecycle of an IND.
-
Core IND Forms
The primary forms required for an IND submission are summarized below.
| FDA Form Number | Official Title | Signed By | When Submitted | Regulatory Purpose |
|---|---|---|---|---|
| FDA 1571 | Investigational New Drug Application | Sponsor | Initial IND | Legal commitment to conduct trial per regulations |
| FDA 1572 | Statement of Investigator | Clinical Investigator | Before site activation | Confirms investigator qualifications and GCP compliance |
| FDA 3674 | ClinicalTrials.gov Certification | Sponsor | Initial IND | Certifies trial registration compliance |
| FDA 3454 | Certification: No Financial Interests | Sponsor | Prior to trial initiation | Declares absence of financial conflict |
| FDA 3455 | Disclosure: Financial Interests | Sponsor/Investigator | If applicable | Discloses financial relationships |
-
FDA Form 1571 – IND Application Cover Sheet
Regulatory Role
FDA Form 1571 serves as the official cover sheet for the IND submission. It is mandatory for all commercial INDs and most investigator INDs. By signing this form, the sponsor commits to complying with FDA regulations, ensuring proper monitoring, maintaining records, and submitting safety updates.
Key Sections of Form 1571
| Section | Description | Regulatory Importance |
|---|---|---|
| Sponsor Information | Legal name and address | Establishes accountable entity |
| Phase of Investigation | Phase I, II, III | Defines development stage |
| Investigational Product | Drug name and indication | Links to scientific modules |
| Commitments | Compliance statements | Legally binding declaration |
| Signature | Sponsor representative | Confirms regulatory responsibility |
Job-Ready Tip: The sponsor name must match exactly with the legal entity mentioned in manufacturing and quality documents. Even minor inconsistencies can trigger regulatory queries.
-
FDA Form 1572 – Statement of Investigator
Regulatory Role
This form is completed and signed by each clinical investigator. It documents investigator qualifications and commitment to conduct the trial in accordance with Good Clinical Practice standards.
Key Components of Form 1572
| Section | Description | Why It Matters |
|---|---|---|
| Investigator Details | Name, address, qualifications | Confirms eligibility |
| Sub-Investigators | Supporting medical staff | Ensures oversight clarity |
| Research Facilities | Site information | Confirms study location |
| IRB Information | Institutional Review Board | Confirms ethical oversight |
| Commitments | Compliance statements | Ensures regulatory adherence |
Operational Requirement
A new Form 1572 must be submitted whenever there is a change in investigator, research facility, or IRB.
-
FDA Form 3674 – Clinical Trial Registration Certification
Regulatory Role
This form certifies compliance with mandatory registration requirements under the FDA Amendments Act. Applicable clinical trials must be registered on ClinicalTrials.gov before patient enrollment.
Key Compliance Elements
| Requirement | Regulatory Expectation |
|---|---|
| Trial Registration | Completed before enrollment |
| Data Accuracy | Must align with IND protocol |
| Updates | Ongoing updates required |
Failure to comply may result in penalties, delayed approvals, or future regulatory complications.
-
Financial Disclosure Forms – FDA 3454 and 3455
Regulatory Role
These forms address potential financial conflicts of interest that may influence clinical study outcomes.
| Form | Usage Scenario | Purpose |
|---|---|---|
| FDA 3454 | No financial interest exists | Certification of compliance |
| FDA 3455 | Financial interest present | Detailed disclosure required |
Financial interests may include equity holdings, proprietary interests, or significant compensation arrangements. Transparency ensures scientific integrity and regulatory trust.
-
IND Form Submission Timeline
Understanding timing is essential for regulatory coordination.
| Stage of Development | Required Forms |
|---|---|
| Initial IND Filing | 1571, 3674 |
| Site Activation | 1572, 3454/3455 |
| Protocol Amendment | Updated 1572 if changes occur |
| NDA/BLA Submission | Financial disclosure summary |
-
Electronic Submission Considerations
All forms must be submitted electronically within the electronic Common Technical Document structure. Proper formatting, signature validation, and document indexing are critical. Regulatory publishing teams must ensure correct module placement and file naming conventions to avoid technical rejection during FDA validation.
-
Practical Competencies for Regulatory Professionals
A job-ready Regulatory Affairs Associate must be able to verify internal consistency across forms, ensure accurate signature collection, maintain version control, and track amendment history. Cross-functional coordination with clinical operations, quality assurance, and legal teams is essential for timely and compliant submissions.
Conclusion
IND forms represent the legal, ethical, and administrative foundation of an Investigational New Drug submission. While scientific data demonstrates safety and quality, these forms establish accountability and regulatory compliance. Mastery of IND form preparation, verification, and lifecycle management is a critical competency for professionals aspiring to work in global pharmaceutical regulatory environments.
